Prevalence of Nonalcoholic Fatty Liver Disease in Familial Mediterranean Fever
Yazarlar (7)
Prof. Dr. Türker TAŞLIYURT Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Prof. Dr. Erkan GÖKÇE Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Doç. Dr. Şafak ŞAHİN Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Asiye Barış Aslan
Prof. Dr. Ayşe Kevser Demir Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Dr. Öğr. Üyesi Süheyla UZUN Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Faruk Kutlutürk
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Endocrine, Metabolic Immune Disorders - Drug Targets (Q3) | ||
| Dergi ISSN | 1871-5303 Dergi Bilgileri (2020) | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 06-2020 |
| Kabul Tarihi | 20-01-2020 | Yayınlanma Tarihi | 17-07-2020 |
| Cilt / Sayı / Sayfa | 20 / 6 / 952–958 | DOI | 10.2174/1871530320666200220125829 |
| Makale Linki | https://www.eurekaselect.com/179589/article | ||
| UAK Araştırma Alanları |
İç Hastalıkları
|
||
| Özet |
| Introduction: Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome (MetS), insulin resistance (IR) and chronic inflammation. Although familial Mediterranean fever (FMF) patients have no symptoms in the periods between attacks, their subclinical inflammation continues. The aim of the present study was to determine the NAFLD frequency in FMF patients and to evaluate their MetS, IR and lipid profiles. Methods: The study included 54 FMF patients and 54 control subjects. The clinical and demographic characteristics of the subjects were recorded, and the patients’ Pras disease severity score was calculated. IR was determined using the homeostasis model assessment (HOMA) index. MetS was diagnosed using the revised National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP ATP III). Hepatic ultrasonography was used to diagnose NAFLD. Results: NAFLD was observed in 15 FMF patients (27.8%) and 14 controls (25.9%). The difference between the groups was not significant (p=0.828). Similarly, no significant difference was found between the two groups for MetS frequency and HOMA index levels. Fasting plasma glucose was significantly higher in FMF patients, whereas differences between the two groups were not significant for lipid levels and other parameters. When FMF patients with and without NAFLD were compared, no significant difference was found in Pras disease severity score, duration of the disease and daily colchicine dose. Conclusion: The present study showed that NAFLD frequency was not increased in FMF patients, and that patients’ MetS frequency, IR and lipid profiles were not different from control subjects. |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Yöksis | 3 |